Statements (70)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:temple
|
| gptkbp:activities |
inhibits type I interferon signaling
|
| gptkbp:approves |
gptkb:2021
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:class |
gptkb:monoclonal_antibody
|
| gptkbp:clinical_trial |
gptkb:TULIP-1
chronic disease management Phase III biologics ongoing research TULIP-2 |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:contraindication |
hypersensitivity to the drug
|
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:dosage_form |
injection
|
| gptkbp:education |
injection technique
|
| gptkbp:effective_date |
January 2021
|
| gptkbp:feedback |
generally positive
|
| gptkbp:frequency |
once every four weeks
|
| gptkbp:healthcare |
available resources
liquid solution limited by cost |
| https://www.w3.org/2000/01/rdf-schema#label |
Saphnelo
|
| gptkbp:indication |
moderate to severe systemic lupus erythematosus
|
| gptkbp:ingredients |
gptkb:anifrolumab
C22 H25 N3 O4 S |
| gptkbp:interacts_with |
live vaccines
immunosuppressive agents caution with other immunosuppressants |
| gptkbp:invention |
patented
|
| gptkbp:is_effective_against |
demonstrated in trials
|
| gptkbp:is_monitored_by |
required during treatment
infection signs |
| gptkbp:is_used_for |
treatment of systemic lupus erythematosus
|
| gptkbp:label |
black box warning
|
| gptkbp:lifespan |
approximately 20 days
|
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:manufacturer |
gptkb:temple
|
| gptkbp:marketed_as |
gptkb:Saphnelo
|
| gptkbp:pharmacokinetics |
subcutaneous absorption
inhibits immune response |
| gptkbp:population |
adults
diverse demographics |
| gptkbp:price |
high
|
| gptkbp:provides_information_on |
included in lupus treatment guidelines
|
| gptkbp:receives_funding_from |
gptkb:Company
|
| gptkbp:regulatory_compliance |
FDA approved
|
| gptkbp:research |
ongoing
|
| gptkbp:research_areas |
rheumatology
|
| gptkbp:research_focus |
autoimmune diseases
|
| gptkbp:safety_features |
generally well tolerated
recommended during use |
| gptkbp:sales |
available in multiple countries
|
| gptkbp:scholarships |
gptkb:stock_market_index
|
| gptkbp:side_effect |
fatigue
headache nausea increased risk of infections infusion-related reactions |
| gptkbp:storage |
store in the refrigerator
|
| gptkbp:supply_chain |
managed by manufacturer
|
| gptkbp:traded_on |
gptkb:Saphnelo
|
| gptkbp:treatment |
reduce flare-ups
improved disease activity |
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:type_of_insurance |
varies by plan
|
| gptkbp:weight |
429.52 g/mol
|